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Abstract
Especially in western civilizations, immune diseases that are driven by innocuous (auto- or allo-) antigens are
gradually evolving to become pandemic threats. A particularly poignant example is type 1 diabetes, where young
children are confronted with the perspective and consequences of total pancreatic b-cell destruction. Along these
disquieting observations we find ourselves equipped with impressively accumulating molecular immunological
knowledge on the ins and outs of these pathologies. Often, however, it is difficult to translate this wealth into
efficacious medicines. The molecular understanding, the concept of oral tolerance induction, the benefit of using
recombinant Lactococcus lactis therein and recent openings towards their clinical use may well enable turning all
colors to their appropriate fields on this Rubik’s cube.
Antigen-specific immune therapy and
recombinant Lactococcus, what, when and why
(Auto-) immune diseases are characterized by aberrant
immune reactions of the immune system towards a lim-
ited number of normally innocuous foreign antigens
(Ags) as is the case for allergies and asthma or self-Ags
in autoimmune diseases. More than 80 different autoim-
mune diseases have currently been identified. These can
target only one organ, such as in type 1 diabetes (T1D),
or multiple organs, such as in rheumatoid arthritis.
Autoimmune diseases affect around 7% of the western
population and this collective prevalence is increasing
alarmingly [1,2]. A similar observation is seen for aller-
gic diseases where the prevalence of 20% in children of
developed countries also slowly rises [3-5]. The underly-
ing events triggering this excessive reactivity remain
unknown, but clearly involve genetic predisposition,
allowing inapt interaction of environmental factors with
the immune system. The general consensus to treat
allergy and autoimmune diseases is altogether unsatis-
factory. The field mostly relies on non-specific systemic
immune suppression or symptomatic treatment which
unfortunately does not address the underlying Ag-speci-
fic reactivity and is usually associated with severe sys-
temic side effects. This can be overcome with Ag-specific
therapeutic strategies targeting only the excessive
immune reactivity. In this review we focus on Ag-specific
tolerance induction in general and develop T1D as a case
study for Ag-driven (auto-) immune diseases, to intro-
duce Ag-specific tolerance restoration by oral administra-
tion of recombinant Lactococcus lactis (L. lactis) bacteria.
This innovative Ag-specific strategy for oral tolerance
induction could open up new therapeutic possibilities in
the emerging field of (auto-) immune diseases. Moreover,
it points to a clear opportunity where recombinant L. lac-
tis could make the difference in medicine.
L. lactis’ genetic engineering and the finding that it
can be used for therapeutic protein delivery was devel-
oped during the previous century. The crux of the idea
is that L. lactis can constitutively produce functional,
eukaryote derived, proteins, without any apparent major
negative effect on its growth and physiology, even when
present in the mucosa of mammalians. The basics
thereof are robust and sound and have changed little, as
can be judged by a wealth of literature [6-14], all using
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the same basic principles. Now is an exciting time to
find that the field has evolved in such a way that it has
become a clinical option now considered by physicians
[15]. The field is ready to address real-life demands and
standards should be set along the existing standard of
care. The aim of this review is to provide such bench-
marking and to show that a viable clinical development
path is realistic. Below we will elaborate on T1D as a
genuine therapeutic need, review current treatment
options, how Ag-specific therapies were conceptually
molded and touch upon the possibilities and downsides
of using oral tolerance induction. We will further
develop our rationale by pointing out that recombinant
L. lactis may well be the ideal tools to bring Ag-specific
oral tolerance induction to reality, with focus on our
recent findings in treating animal models of T1D.
Finally, we will give a general overview of our accom-
plishments in clearing the clinical path for recombinant
L. lactis.
Type 1 diabetes
T1D is an eminent example of a well-studied chronic
autoimmune disease characterized by the selective
destruction of insulin-producing pancreatic b-cells by
pathogenic self-reactive CD4+ and CD8+ T cells. The pre-
valence of T1D is estimated to number up to more than
20 million patients worldwide with the incidence in chil-
dren under the age of 5 to double between 2005 and
2020 [16,17]. With the help of several in vivo models,
such as the biobreeding rat and the non-obese diabetic
(NOD) mouse, both of which develop T1D sponta-
neously, more insight has been gained in the mechanism
of the autoimmune cascade. Due to speculative triggers,
pancreatic b-cell Ags become presented by Ag-presenting
cells that have infiltrated pancreatic islets (Figure 1)
[18,19]. This will activate and expand pathogenic islet
Ag-specific T cell populations [19,20] and eventually the
natural balance between auto-reactive T cells and their
regulatory counterparts is disturbed, leading to tolerance
breakdown and a progressive b-cell loss (Figure 1). The
immanent diminished release of the glucose-regulating
hormone insulin will lead to elevated blood glucose levels
or hyperglycemia. As for most autoimmune diseases
there is no specific cure for T1D. Patients can only rely
on exogenous insulin substitutions to normalize glucose
levels, which however do not prevent complications of
the pathology, thereby making it difficult to pursue nor-
mal life quality and normal lifespan.
Standard of care: systemic immune suppression,
which comes at a price
So far, current therapeutic strategies applying systemic
immunosuppression have given the best results in clini-
cal studies. Systemic immunomodulators, such as
cyclosporine A and monoclonal anti-CD3 antibodies,
target the general immune system in order to neutralize
the b-cell-specific autoimmune reactivity.
Cyclosporine A, a pioneer amongst immunosuppres-
sive agents, blocks immunity at one of its most crucial
steps. This polypeptide inhibits T cell activation by inhi-
biting autocrine IL-2 synthesis and thus cell prolifera-
tion. The drug has already demonstrated efficacy in
enhancing renal transplantations and preventing rejec-
tions [21]. Several clinical studies in newly-diagnosed
type 1 diabetic patients showed disease remission asso-
ciated with enhanced preservation of b-cell function by
cyclosporine treatment [22-24]. However diabetes rever-
sal was never sustained and was accompanied with
severe forms of nephrotoxicity [25-27].
Monoclonal anti-CD3 antibodies, targeting the T cell
receptor (TCR), are a unique class of immunomodulators
in that they interact with both pathogenic effector T cells
and regulatory T cells (Tregs, T cells that sustain toler-
ance). This dual mechanism of action works in two phases.
In a first phase, recently activated T cells are transiently
depleted or made blind to Ag by shedding and internaliza-
tion of the TCR/anti-CD3 complex [28,29]. In a second,
long-term phase, anti-CD3 antibodies preserve and induce
Tregs [30,31]. In recently-diagnosed (early) diabetic NOD
mice a short-term low-dose course of anti-CD3 at a total
dose of 25 μg could reverse diabetes in 80% of the treated
mice [32,33]. These promising preclinical studies have led
to construction of two humanized anti-CD3 antibodies,
namely hOKT3y1 (Teplizumab) and ChAglyCD3 (Otelixi-
zumab) and their clinical testing in newly-diagnosed type
1 diabetic patients [34,35]. Both drugs could preserve b-
cell function for up to one year, after which the b-cell
destruction gradually continued [36-38]. A follow-up
study of Otelixizumab showed a significant preservation of
b-cell function for up to 4 years post-treatment [39].
Increasing administered doses of Teplizumab with 40%
did not ameliorate therapeutic efficacy and was associated
with increased presentation of drug-related side effects,
such as cytokine release, headaches, fever and rash [40]. In
the Otelixizumab trial, several patients experienced a tran-
sient and self-limited reactivation of the Epstein-barr
virus. However due to the positive therapeutic outcomes
several phase III studies were conducted. The DEFEND-1
study, using Otelixizumab, did not meet its primary end-
point, mainly due to the unsubstantiated choice of valida-
tion parameters in addition to ad random choices made in
dose reductions [41]. A second phase III study with Tepli-
zumab (The Protégé study) also missed its primary end-
point. However, post-hoc analyses in subgroups of
patients revealed better preservation of b-cell function
when anti-CD3 was given in a full dose regimen, namely
17 mg administered at baseline and again after 6 months
[42,43]. Similar observations of preserved insulin
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Figure 1 T1D onset and development. Genetic predisposition and environmental exposure interact with an impaired immune system to break
tolerance towards pancreatic insulin-producing b-cells. Initial b-cell destruction leads to release of b-cell-specific auto-Ags, such as pro-insulin,
GAD65, IA-2 and others. Upon auto-Ag-recognition, auto-reactive T cells expand, migrate to the pancreas (insulitis) and induce progressive b-cell
destruction. In healthy individuals these auto-reactive T cells are controlled by regulatory T cells (Tregs). However, in T1D patients this regulatory
counterpart is impaired causing a significant imbalance of this immune control mechanism. In addition, auto-Ag-activated B lymphocytes
produce b-cell-specific auto-Abs. When patients present with clinical symptoms caused by insufficient b-cell-mass and subsequent aberrant
glucose regulation, this auto-Ab profile allows for specific diagnosis of immune-mediated T1D. In general, T1D patients can only rely on
exogenous insulin substitutions to stabilize their glucose metabolism. Possible therapeutic targets involved in the pathology of T1D are
highlighted (gray boxes). Both systemic immunomodulation, amongst others monoclonal anti-CD3 antibodies and cyclosporine A, and Ag-based
approaches have been explored to restore tolerance.
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production with high-dose anti-CD3 were seen in the
Autoimmunity-Blocking Antibody for Tolerance in
Recently Diagnosed Type 1 Diabetes (AbATE) study [44].
Although the DEFEND-2, Protégé Encore and the SUB-
CUE trial were terminated, several investigator-led clinical
studies with anti-CD3 are still being conducted. The At
Risk-study is designed to evaluate whether teplizumab can
help to prevent or delay disease onset in relatives at risk for
T1D (http://ClinicalTrials.gov Identifier NCT01030861).
The Delay-study evaluates whether Teplizumab will pre-
vent the loss of insulin secretory capacity in individuals
with recent, but not recent-onset, T1D (http://Clinical-
Trials.gov Identifier NCT00378508). Also, a Phase I study
on subcutaneous administration of Otelixizumab in T1D
patients is ongoing (http://ClinicalTrials.gov Identifier
NCT00946257). Taken together, these data still support
anti-CD3 progress to full-scale phase III trials.
Although Ag-nonspecific systemic immune approaches
have shown some therapeutic efficacy in the context of
T1D - b-cell preservation, postponing the gradually
decline in insulin production - one cannot but acknowl-
edge that sustainable long-term effects could not be
achieved. In addition, non-specific immune targeting
provokes severe systemic side effects. Broad immune
suppression renders the treated patient highly susceptible
for pathogenic infections and may lead to the formation
of malignancies. Notwithstanding the beneficial effects
achieved with systemic immunomodulators, legitimate
health risks remain associated with such therapeutic stra-
tegies. In conclusion it is fair to state that the shortcom-
ings of current approaches limit access to effective
therapies.
Experimental Ag-specific T1D therapies are safe
but show lack of efficacy
In most (auto-) immune diseases immune reactivity is
restricted towards a limited number of (auto-) Ags.
Auto-Ags targeted by auto-reactive T cells are continu-
ously emerging and their disclosure relies heavily on the
identification of autoantibodies present in patients or dis-
ease-predisposed individuals. Ag-specific control of these
auto-reactive T cells remains the ultimate therapeutic
approach, eliminating the risk of any unwanted systemic
immune reaction.
Ag-specific approaches for (auto-) immune diseases
require careful consideration. Introducing selected (auto-
) Ags to a non-tolerogenic, already primed environment
can boost (auto-)immune reactivity and aggravate dis-
ease. Correct choice of Ag, timing (window of opportu-
nity), dose and frequency of administration are key
aspects to take into consideration [45]. Accurate extrapo-
lation of these parameters from preclinical animal, mur-
ine and porcine, models to man however remains a
challenging task. Extrapolation should not just rely on
mere body weight calculation but needs to take into
account different physiological parameters, amongst
others energy metabolism and renal function. Profound
pharmacokinetic and pharmacodynamic studies in differ-
ent animal models need to be carefully conducted to pre-
vent unexpected events. Proper choice of adjuvants can
favor a tolerogenic response. One example is the use of
aluminum salts, which effectuates a Th2 response on top
of enhanced Ag delivery and activation of Ag-presenting
cells [46,47]. Moreover, the mode of administration
remains crucial for tolerance inducing strategies.
Several pancreatic islet auto-Ags are involved in the
pathogenesis of T1D, of which (pro-)insulin, glutamic acid
decarboxylase 65 (GAD65) and tyrosine phosphatase-like
protein ICA152 (IA-2) are the most prominent [48-50].
Parenteral, oral or nasal administration of said auto-Ags
could prevent or delay T1D in the NOD mouse model
underlining the prophylactic potential of Ag-specific thera-
pies [51-55]. None of these preclinical studies were effec-
tive in established disease. So far, apart from a few
exceptional cases dealing with cryptic epitopes, none of
these preclinical studies have shown exacerbation of the
autoimmune response, thereby highlighting their safe pro-
file [56]. Hence, clinical translation has been disappointing.
Multiple studies administering subcutaneous or intranasal
insulin or GAD65 to newly-diagnosed T1D patients or to
autoantibody-positive T1D-relatives did not improve the
clinical outcome [57-62]. One study administering unpro-
tected oral insulin induced a delayed onset of T1D, albeit
only in a subgroup of diabetes-prone individuals with high
baseline insulin autoantibodies [60]. Despite the disap-
pointing absence of clinical efficacy, none of these clinical
studies showed signs of disease aggravation, again reiterat-
ing the inherent safety of using these selected Ags.
Oral tolerance induction: silver bullet, unmined
field or the ever promise?
A number of studies point to the mucosal immune sys-
tem of the gastrointestinal tract to induce Ag-specific
suppression, relying on its privilege to induce tolerance
to orally administered Ags. The lymphoid tissue of the
gut covers more than 260 m² and contains one of the
highest numbers of lymphocytes, rendering it the largest
immune organ of the body. This mucosal immune system
is excellently equipped to judge on unresponsiveness
towards intestinal commensals and harmless food Ags
and responsiveness towards pathogens. To maintain
intestinal homeostasis, anti-inflammatory cytokines such
as TGF-b and IL-10 are abundantly present in the gut
and together with retinoic acid they create a highly tol-
erogenic environment [63]. In addition, excessive muco-
sal production and luminal secretion of IgA assists in
neutralizing exotoxins and microbes. Sampling and pre-
senting of luminal Ags is mediated by specialized M cells
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and dendritic cells, or even by epithelial cells through
transcytosis. Gut Ag-presenting cells intrinsically favour
the induction of Foxp3+ Tregs in the gut-draining lymph
nodes rather than activating effector T cells. Further,
imprinting of gut-homing receptors (amongst others
a4b7 and CCR9) guaranties the return of these Ag-speci-
fic Tregs to the gut [64]. Oral Ag administration makes
use of these tolerogenic characteristics to suppress sys-
temic Ag-specific reactivity. The underlying mechanism
of oral tolerance induction depends on the dose of Ag
administered, where, at least in preclinical models, low
repetitive doses favour the induction of Tregs and high
doses favour deletion or anergy of effector T cells [65].
Oral tolerance induction has successfully been applied in
experimental autoimmune disease models such as col-
lagen induced arthritis [66] and experimental autoim-
mune encephalomyelitis [67,68] and relates to the
induction of Tregs in these experimental settings [69-71].
Suppressive cytokine production by Tregs (IL4, IL-10
and TGF-b) induces bystander suppression to other
(auto-)Ags presented in the close vicinity. This spreading
of regulatory responses can even make it redundant to
provide the primary Ag, an advantage that can be used in
the context of T1D where several auto-Ags are enrolled
in the autoimmune cascade and the primary auto-Ag is
not yet unambiguously identified.
Patients would definitely prefer the elegance of this
safe and easy way of administration above the inconve-
nience of parenteral injections. The main challenge
faced with oral tolerance induction is to efficiently deli-
ver Ag doses of superior quality to the intestinal
mucosa. Studies unveiled that, unless large quantities
are used, intestinal passage causes Ag degradation
before it can reach the mucosal immune system of the
gut [72,73]. The cost of administering large quantities of
high quality Ag being prohibitive makes that there is a
strong need for adequate and effective vehicles to con-
trol oriented Ag-delivery to the gastrointestinal immune
system. Moreover, if such vehicles could also deliver
mucosal immune modulators such as IL-10, they could
be pivotal in raising tolerogenic immune responses.
L. lactis, a top-notch carrier for tolerance
induction
Along with the concept of using recombinant L. lactis for
vaccination (recently reviewed [74]) arose the idea of mak-
ing this host a carrier for tolerance induction (Figure 2). It
is indeed not far-fetched thinking to engage an innocuous,
Figure 2 L. lactis can bridge the gaps towards Ag-specific immune therapy. State of the art research on (auto-) immune diseases allows for
mechanistic understanding of these pathologies, in terms of onset, precise localization (red circle), cellular compartment and specificity of the
auto-Ag (Ag; wedge). The current standard of care exists of systemic immune suppression which may alleviate some aspects of the immune
pathology but very often, due to its systemic and Ag-nonspecific nature, comes associated with moderate to even severe toxicity in otherwise
non-affected organs. Purified Ag (blue triangle), delivered through the oral route, aims to make proficient use of inherent oral tolerance
induction at the intestinal mucosal immune system to provoke Ag-specific suppression of the immune disease without affecting areas that do
not share the Ag (X). This route of administration however suffers from major practical obstacles which make it difficult to administer sufficient,
high quality Ag to the intestinal mucosa. To circumvent this, recombinant L. lactis expressing the Ag (blue circle holding white triangle) can be
delivered through the oral route. These bacteria can then synthesize Ag of reproducible quality directly at the intestinal immune system and by
co-synthesis of immune modulatory components can further enhance tolerance induction. In this way, Ag-specific oral tolerance induction is
rendered practically feasible.
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well-known food derived host for dampening rather than
stimulating immune reactions.
Initial studies in animals show alleviation of allergic
responses subsequent to the administration of recombi-
nant L. lactis. Mucosal - oral or intranasal - administration
of recombinant L. lactis that secrete bovine beta-lactoglo-
bulin (BLG) leads to the induction of BLG specific fecal
IgA [75]. T helper (Th) 1 Th1 cells stimulate cellular
rather than humoral immunity and antagonize Th2 cells,
which often underlie allergy. Oral application of L. lactis
secreting BLG prior to sensitization enhances Th1
response in serum (increased IgG2A, decreased IgE) and
ex-vivo splenocytes (increased IFNg). However, in some
settings, splenocytes showed increased interleukin (IL)-5
(Th2). Cellular location of the Ag seems to matter: intra-
cellular BLG seems to drive Th2 response while secreted
BLG enhances both Th1 as well as Th2 features, the latter
associated with a - less pronounced - IgE induction which
is suggestive for reduction of sensitization. On the other
hand, IgA, a desired feature for the establishment of toler-
ance, is induced most prominent in the setting where IgE
is not reduced versus the reference [76]. When inoculated
intranasal prior to sensitization, recombinant L. lactis pro-
ducing intracellular major birch pollen allergen BetV1
decrease allergic response to BetV1. Specific serum IgE
was decreased and both specific IgG2A and IgG1 are
increased. Broncheoalveolar lavages show reduced IL-5
and reduced number of eosinophils, while, both in the air-
ways as well as in the gut, specific IgA was increased [77].
Intranasal inoculation of L. lactis producing BLG post sen-
sitization reduced mucosal as well as systemic IgG1 and
showed diversion of splenocytes towards Th1 [78]. Taken
together, these reports propose the induction of IgA and
the avoidance of Th2 response as prominent endpoints
and show that - at least to a certain extent - these can be
met by use of recombinant L. lactis. The reported synth-
esis of other known allergens such as peanut allergen Ara
h 2 [79] and buckwheat major allergenic storage protein
[80] demonstrates that the repertoire of potential immune
therapeutic L. lactis is gradually expanding and awaits
experimentation.
A limited number of reports demonstrate that toler-
ance induction through recombinant L. lactis can be
expanded to auto-Ags. Heat shock proteins (Hsp) form a
class of proteins involved in the management of cellular
stress and are drivers of inapt immune reactions and
their associated pathologies. Bacterial Hsp proteins can
provoke cross reactivity to their human counterparts,
these then in turn becoming auto-Ags. Oral administra-
tion of L. lactis producing Hsp65 shows potential for
immune intervention. L. lactis Hsp65 attenuates athero-
sclerosis in susceptible mice. Both secreted as well as
intracellular mycobacterial Hsp65 reduced splenocyte
proliferation and atherosclerotic lesions [81]. Further,
L. lactis producing Mycobacterium leprae Hsp65 pre-
vented experimental autoimmune encephalomyelitis in
mice by Treg induction [82].
These studies show that, as a carrier for the delivery
of immune-pathological epitopes, L. lactis undoubtedly
holds promise for anti-allergic and autoimmune therapy:
this carrier certainly does not lead to worsening of the
autoimmunity or allergy. Caution however should be
taken when translating to human medicine. A funda-
mental aspect of the above mechanisms involves the
induction of Th1 responses leading to avoidance of
allergic - Th2 - responses. A large portion thereof will
evidently be provoked by IFNg production, which in
turn may well be a result of the challenge of naïve mice
with L. lactis, which is not part of its diet and/or the
gastrointestinal microflora. Left alone the fact that Th1/
Th2 distinction may not be as clear in humans as it is
in mice, nearly no humans are naïve to L. lactis, again
due to diet composition. The case may even be more
obscure for other bacterial hosts as it will be difficult if
not impossible to predict which part of the population
has been exposed to any said strain or bioactive compo-
nent thereof. Novel therapeutic approaches should
therefore carry sufficient immune modulatory informa-
tion, for which exists a rationale that substantiates
mouse to human translation, enabling them to act
autonomous from primary immune reactions that occur
upon naïve encounters.
Many probiotic strains - lactic acid bacteria and other
- exert beneficial health effects through surface and
secreted proteins, glycoproteins, teichoic acids and lipo-
polysaccharide. To provoke responses, these molecules
interact with pattern recognition receptors of the host
[83]. A number of reports show that also L. lactis strains
can exert similar immune modulatory effects [78,84-86],
amongst others driven by teichoic acids [87], also in
conjunction with purified allergen [88]. Again, this
shows that L. lactis in itself is a good candidate delivery
vehicle. However, for the reasons described above, cau-
tion should be taken when translating these effects to
use in humans. A more rational approach for this type
of drug design therefore lies in applying signaling path-
ways derived from the immune system that have shown
to be paralleled in both the experimental animal model
as well as in humans. The combination of selected
recombinant Ag and cytokines therefore allows for more
predictable steering of pathways for tolerance induction.
The initial findings that cytokines could be delivered to
the mucosa through secretion by recombinant L. lactis
led to the development of a new type of immune modula-
tory L. lactis [6,7]. Along these lines of thinking, IL-10
secreting L. lactis [89,90] and L. lactis producing IL-12
have been used for anti-allergic therapy [13]. The latter
approach provides a good alternative to influence
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Th1/Th2 balance, as shown in ovalbumin-induced
asthma [91].
Recombinant L. lactis can induce Ag-specific
reduction of cellular immunity
Ag-specific tolerance induction remains the ultimate goal
to treat autoimmune and allergic diseases. Oral administra-
tion of L. lactis delivering Ags has already demonstrated
efficacy by inducing Ag-specific immune suppression. Hui-
bregtse et al. report a detailed mechanism for T cell-driven
Ag-specific tolerance induction by studying oral adminis-
tration of recombinant L. lactis secreting ovalbumin (LL-
OVA) in a mouse model carrying transgenic OVA-specific
T cell receptors [92]. OVA-sensitized transgenic mice were
exposed to oral LL-OVA. Subsequent, OVA-specific toler-
ance was assessed by delayed-type hypersensitivity mea-
sured by ear thickening. L. lactis-mediated intestinal
delivery of OVA reduced OVA-specific hypersensitivity in
this experimental mouse model. This systemic suppression
could not be obtained with purified OVA underlining the
added value of L. lactis as a mucosal carrier, especially after
sensitization. In vitro re-stimulation of the ear-draining
lymph nodes, spleen and gut-associated lymph nodes with
OVA revealed a higher IL-10 production in the LL-OVA
treated animals, suggesting the involvement of a Treg com-
partment. Further in vitro research showed that LL-OVA
feeding suppressed OVA-specific proliferation of CD4+
splenocytes and this seemed to be effectuated by induced
CD4+CD25- T cells functioning in a TGF-b-dependent
way. Adoptive transfer of this CD4+CD25- T cell compart-
ment suppressed OVA-specific reactivity in OVA-immu-
nized balb/c recipient mice. Taken together, this study was
the first to demonstrate efficacy of recombinant L. lactis in
inducing Ag-specific Tregs and subsequent Ag-specific tol-
erance in an experimental mouse model. Moreover it
clearly underlines the added value of L. lactis mediated
delivery over applying purified Ag in mucosal therapy.
L. lactis mediated Ag delivery allows for intervention sub-
sequent to sensitization where purified Ag only allows pre-
ventive strategies. In addition, the critical amount of OVA
required was reduced by several orders of magnitude,
which is, as stipulated above, a highly desirable goal.
Can this approach be used to induce Ag-specific
reduction of cellular immunity in a host of wild type T
cell repertoire? This appears to be the case indeed, as
oral L. lactis secreting the deamidated DQ8 gliadin epi-
tope (one of the drivers of celiac disease) shows a major
suppression of intestinal and systemic DQ8-restricted T
cell responses in NOD AB° DQ8 transgenic mice [93].
L. lactis: the gateway towards a novel, Ag-specific
T1D therapy
Also in the context of autoimmunity, oral administra-
tion of recombinant L. lactis that secrete auto-Ags
shows to be a valid approach to restore tolerance. A
new therapeutic strategy for T1D was devised by use of
recombinant L. lactis secreting human pro-insulin
(PINS) and IL-10 (LL-PINS+IL-10) to recently-diag-
nosed diabetic NOD mice [94]. A combination therapy
(CT) of LL-PINS+IL-10 with a short-course of subthera-
peutic doses anti-CD3 Abs reversed diabetes in 59% of
treated mice in comparison to 25% with anti-CD3
monotherapy and 15% when using LL-PINS+IL-10
alone. Moreover anti-CD3 plus LL-PINS reversed dia-
betes in 49% of treated mice highlighting the importance
of mucosal co-delivery of IL-10 and Ag. This observa-
tion underlines the great potential of combination stra-
tegies: systemic immunomodulation is combined with
Ag-specificity, thereby providing specificity and increas-
ing efficacy. As such, toxic dosages of systemic immuno-
modulators can be reduced to non-harmful - but as
such sub-therapeutic - levels.
Successful CT was associated with preservation of
remaining b-cell mass, not with increased proliferation or
generation of new b-cells. Moreover, cured CT-treated
animals showed increased frequencies of CD4+CD25
+Foxp3+ Tregs in pancreatic-draining lymph nodes.
These Tregs exhibited polyclonal and Ag-specific sup-
pressive capacity in vitro in addition to disease-specific
suppressive capacity in vivo. Also, locally in the pancreas,
increased frequencies of proliferating Foxp3+ Tregs could
be detected, further suggesting that CT of low-dose anti-
CD3 with LL-PINS+IL-10 induces PINS-specific Tregs
that migrate to the site of inflammation and inhibit
further b-cell destruction.
To verify whether other auto-Ags can induce or
enhance diabetes remission, recombinant L. lactis secret-
ing T1D-related auto-Ag GAD65 have been tested suc-
cessfully in a similar setting [95]. Interestingly, LL-GAD
CT retained a similar 60% diabetes remission even in
severely hyperglycemic (late) NOD mice as opposed to
LL-PINS+IL-10 CT. This could be explained by the
hypothesized primary role for PINS in the autoimmune
cascade followed by GAD65 reactivity and suggests that
LL-GAD CT is more widely applicable and can be used
in more advanced stages of T1D.
Bringing recombinant L. lactis to the clinic
Moving recombinant L. lactis forward to clinical experi-
mentation is the next step in achieving the ultimate goal:
the development of a novel pharmaceutical product. Key
aspects encompass clear and unambiguous genetic engi-
neering, undisputable safety profile and high quality chemis-
try, manufacturing and controls (CMC). The whole of these
will be at the center of the authorities’ scrutiny and precise
approach will lay the foundation for regulatory approval.
The regulatory approval process to use live recombi-
nant bacteria as drugs faces unique challenges. First,
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research and production operations need to be elevated
to the standard of the pharmaceutical industry. Accord-
ing to guidelines from “International Conference on
Harmonization of Technical Requirements for Registra-
tion of Pharmaceuticals for Human Use” (ICH), produc-
tion of pharmaceuticals must comply with good
manufacturing practice (GMP). Product quality and con-
sistency needs to be demonstrated, including testing of
identity, purity, potency and stability. Animal toxicology
studies must demonstrate the safety of the drug product
before it can be administered to humans. Second, drugs
that are deliberately releasing recombinant organisms
need to follow special guidelines addressing environ-
mental containment and eradication. As an inherent
part of communication towards society of its know-how
on environmental safety, the clinical trial sponsor will
need to demonstrate appropriate risk assessment and
must avail of a superbly functioning containment system
[96].
The bacterial organism of choice is by absolute prefer-
ence well described and with a long standing history of
safe use in humans. For this it should have very few if
any case records in medical literature. Growth of the host
should be susceptible to a panorama of antibiotics but it
may be an advantage if a certain number of those will
still allow for Ag expression. Residence of the organism
inside the host - whether transient, lingering or capable
of active colonization - will be determining the degree to
which a handle on dosage and timing will exist, both key
aspects of a clear pharmacodynamic profile. From this
point of view, L. lactis has a clear advantage over other
hosts. It is a well described, non-colonizing species, with
an excellent track-record of safe use in humans. More
specific, as described in detail above, many groups
showed safety in tolerance induction in that recombinant
L. lactis abstain of any aggravation of the studied (auto-)
immune pathologies. Further, L. lactis is susceptible to a
range of antibiotics that prevent growth but not recombi-
nant protein expression.
Genetic engineering must be robust and should pre-
clude the use of plasmids and other mobile elements
and should be free of antibiotic selection markers. This
makes the bacterial chromosome, at sites away from
transposons and IS elements, the desired carrier for Ag
gene expression. The genetic engineering must ensure
environmental containment, eventually by a combina-
tion of inherent features of the species and by recombi-
nant traits [96].
Following demonstration of biological activity in ani-
mals, drug development - also when starting from a
recombinant bacterium - follows set rules. As for any
pharmaceutical, establishing a medicinal product requires
the set-up of adequate CMC. The process of genetic
engineering, strain selection and maintenance of a
research cell bank is straightforward and well known to
most researchers in the field. These activities are - almost
by definition -non-GMP processes. Documentation must
nevertheless be of the highest quality because at this
stage, identity of the active component is fixed and stabi-
lity of the transgenic trait and containment system must
be demonstrated. Every activity beyond the final strain
selection - the establishment of a master cell bank, the
development of the processes for fermentation and bio-
mass concentration as well as lyophilization to produce a
drug substance in bulk and stability studies - need to
comply with GMP standards and documentation should
be recorded accordingly. All segments of the production
process must be robust - i.e. should not overly depend on
any variable - and scalable. All raw materials have to be
of clinical grade and by high preference, if not exclu-
sively, free of all animal-derived products. The product
must be safe and therefore the very initial development
phase will encompass toxicology studies in relevant ani-
mal species and small, phase I safety and tolerability stu-
dies in humans. The drug must be sufficiently stable to
allow treatment of thousands of patients. At any of the
relevant stages during processing, thorough and reliable,
validated documentation is required.
Approval or rejection of an application to perform a
clinical trial resides with national or European agencies.
Initially, all regulatory systems afford drug developers a
certain period of scientific advice during which they can
be approached to discuss future steps of product devel-
opment. Such a consultancy phase allows the listing of
supporting studies the agencies consider necessary,
including additional animal proof of concept and safety
studies. Without this window of initial communication
before the filing of the final product, a late discovery of
gaps in the data in a more advanced phase could derail
an entire project.
Although all clinical trial applications require data on
animal pharmacology and toxicology, manufacturing
information, clinical protocols and investigator informa-
tion, regulatory agencies in different countries may have
unique requirements which need to be taken into account
when setting up a dossier. When comparing Europe vs.
North America the contents of the application may vary
substantially, mainly differing in whether all or part of the
existing documentation must be included. U.S. authorities
(U.S. Food and Drug Administration; FDA) require having
all of the documentation in the file. European authorities
(European Medicines Agency; EMA) request an overview
on strategy and a product description, but supporting data
remain at the sponsor, eventually to be presented upon
request. Canadian authorities (Health Canada) have very
concise regulations, and will request all documentation to
be kept at the study sites, again to be presented upon
request. Where most authorities will require clinical trial
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applications (CTA) per specific trial; U.S. FDA utilizes the
“open” investigational new drug (IND) process. The IND
is product specific and the sponsor continues to submit
new data along the road towards market approval.
Any clinical trial involving recombinant organisms will
be categorized as “contained use” or “deliberate release”,
the first requiring absolute physical containment, the
latter harmonizing the use of the recombinant organism
and its release in the environment. For most authorities
the application for contained use - provided physical
containment is absolute, which is left at the discretion
of the sponsor - is relatively straightforward. Medical
use however is almost inherently coupled to deliberate
release of the recombinant organisms in the environ-
ment. Regulations on the deliberate release of recombi-
nant organisms differ between countries, and the
application process involves differing steps. The U.S.
system sets in place the NIH Recombinant DNA Advi-
sory Committee (RAC) to advise local authorities in
their decisions when overseeing a clinical trial applica-
tion involving recombinant organisms. Decisions on the
use of recombinant organisms however remain with the
clinical centers. Canadian and European authorities will
decide on the use of recombinant organisms on a
national level. Canadian authorities apply no guidelines
on the use of recombinant organisms. The Canadian
environmental protection agency however will judge any
novel product - regardless of its origin - to be entered
into Canada on its potential environmental impact upon
“deliberate” release. The “new substance notification”
application undergoes thorough scrutiny, in the specific
case of recombinant microflora on data to demonstrate
the effectiveness of the containment system and experi-
ments and literature that allow judgment on environ-
mental impact. Specific for the European review and
approval process is the scrutiny for products involving
recombinant DNA, which is regarded as fundamentally
different from conventional approaches.
The above, complex path is essential to guarantee
safety to humans. When entering into human tolerance
induction therapy, this path is however not expected to
differ extensively from that of earlier clinical trials with
recombinant L. lactis that have been conducted success-
fully (http://ClinicalTrials.gov Identifiers NCT00729872
and NCT00938080 [15]). Therefore, the conduct of clin-
ical trials using recombinant L. lactis for Ag-specific tol-
erance induction has moved beyond the visionary to
become practicable.
Conclusion: L. lactis can bridge the gaps towards
Ag-specific immune therapy
Immune diseases driven by innocuous - auto or allo -
Ags are rapidly emerging. As judged from their global
evolution, this phenomenon goes along with western
lifestyle [97,98]. The manifestations of these diseases
come in a wide variety, from “unpleasant” to “life threa-
tening when left untreated”. Despite our growing
mechanistic understanding, the current standard of care
remains unsatisfactory in many cases. Shortcomings
range from partial and temporal relief to being asso-
ciated with highly undesirable, widespread toxic side
effects. It will be necessary to harness our molecular
immunological understanding in order to develop medi-
cation that can reach the suitable outcome: Ag-specific
tolerance induction devoid of side effects. Oral toler-
ance, a system that manages the discrimination between
friend and foe in the intestine, is one possible entry into
this field. However it remains largely untapped because
of practical and technological hurdles. In prophylactic
settings, clear demonstration of Ag-specific oral toler-
ance induction has been given in experimental animals. It
however remains very difficult to deliver sufficient
amounts of high quality Ag to the human intestine. Rather
than being merely preventive, L. lactis Ag-delivery has
shown suitable to support intervention strategies in
Ag-driven immune diseases. With recombinant L. lactis
we avail of the technological tools to bridge between our
molecular understanding and the practicalities of human
medicine. We can engineer L. lactis to produce (auto-)
Ags and immune modulatory factors and genetic engi-
neering is such that it is safe to use. Large scale GMP
manufacturing has been established and quality controls,
both critical components for clinical experimentation
under ICH guidelines, are in place. All this has been
shown necessary and sufficiently elaborated to allow suc-
cessful completion of the regulatory approval process. We
now find ourselves at a pivotal point: we have the tools
and experience to allow recombinant L. lactis to make a
difference in healthcare by helping out people suffering
from prominent but largely unmet medical needs.
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